Advanced Solid Tumor Clinical Trials in Salt Lake City, Utah

13 studies are recruiting for advanced solid tumor in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

3. Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1013, The University of Utah, Salt Lake City, Utah

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

4. A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

   This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah, Salt Lake City, Utah

   Locations

   11 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05765851 on ClinicalTrials.gov

5. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

6. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

   This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   36 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05875168 on ClinicalTrials.gov

7. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

8. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

   This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   8 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06352359 on ClinicalTrials.gov

9. A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

   This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   8 in total

   Run by

   Peel Therapeutics Inc

   See if you can join NCT05329103 on ClinicalTrials.gov

10. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Intermountain Health, Salt Lake City, Utah

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

11. Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

    Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study no…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Huntsman Cancer Institute - University of Utah, Salt Lake City, Utah

    Locations

    7 in total

    Run by

    Strand Therapeutics Inc.

    See if you can join NCT06249048 on ClinicalTrials.gov

12. A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

    This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalati…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Huntsman Cancer Institute, Salt Lake City, Utah

    Locations

    4 in total

    Run by

    Latticon Antibody Therapeutics, Inc

    See if you can join NCT06277219 on ClinicalTrials.gov

13. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    University of Utah, Salt Lake City, Utah

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov